Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

June 5, 2019June 5, 2019

Ratio Between FVIII and Von Willebrand Factor Predicts Relapse in Patients with Acquired Hemophilia A, Study Reveals

News

The ratio between the blood clotting protein factor VIII (FVIII) and the von Willebrand factor (VWF) may be a reliable biomarker of recovery and relapse in patients with acquired ... Read more

April 12, 2019April 12, 2019

Improved Care May Explain the Higher Prevalence of Male Hemophiliacs in Indiana, Study Reports

News

Fewer HIV infections and better care may explain the higher prevalence of hemophilia in male patients in Indiana between 2011 and 2013 than previously reported in six other states, ... Read more

March 22, 2019March 22, 2019

Healthcare Costs Higher with Bypassing Agents than Factor Replacement Therapy in Hemophilia A, Study Reports

News

Treatment of hemophilia A with bypassing agents is associated with significantly higher costs than with factor replacement therapy, according to a real-world study in the U.S. The study, “Healthcare ... Read more

March 18, 2019March 18, 2019

Prophylaxis Partially Prevents Bleeding in Severe Hemophilia A Patients, Real‐world Study Finds

News

Regular preventive treatment is able to at least partially prevent bleeding episodes in adolescent and adult males with severe hemophilia A and without inhibitors, according to a real-world study. The ... Read more

February 6, 2019February 6, 2019

First Patient Treated in Phase 3 Trial of AMT-061 in Hemophilia B

News

A Phase 3 clinical trial of treatment candidate AMT-061 for severe and moderately severe hemophilia B has treated its first patient. The open-label HOPE-B study (NCT03569891) is testing the safety ... Read more

January 21, 2019January 21, 2019

Activities and Levels of Bleeding Risk They May Carry Ranked by Physical Therapists

News

Repetitive movements, fitness level, and prolonged and competitive physical activity are among the factors that raise bleeding risks for people with hemophilia taking part in such activities, a study based ... Read more

December 12, 2018December 12, 2018

Eloctate and Alprolix Show Long-Term Effectiveness for Hemophilia in Extension Studies

News

Treatment of severe hemophilia A with Eloctate and hemophilia B with Alprolix was safe and improved the patients’ annualized bleed rates (ABRs) over four years, according to the results of two extension studies ... Read more

November 26, 2018November 26, 2018

Potential Gene Therapy for Hemophilia A, AMT-180, May Treat Patients Regardless of Inhibitor Status, uniQure Says

News

A gene therapy from uniQure in early testing, called AMT-180, has the the potential to treat all hemophilia A patients, including those with inhibitors, according to the company. Hemophilia A is caused ... Read more

November 12, 2018November 12, 2018

Patient Enrollment Ongoing in Phase 3 Trial of AMT-061 for Hemophilia B, uniQure Says in Update

News

uniQure is continuing to enroll participants for its global Phase 3 trial (NCT03569891) testing the potential gene therapy AMT-061 in men with severe or moderately severe hemophilia B, according to an ... Read more

October 15, 2018October 15, 2018

Rate of Total Joint Replacement Similar in Hemophilia A and B, Study Reports

News

Total joint replacement (TJR) is more common in severe hemophilia patients requiring more frequent treatment, according to a population-based study in Taiwan. The findings also revealed that the incidence ... Read more

Pin It on Pinterest